Divergent Paths, Convergent Goals: Institutional Experiments in Cell and Gene Therapy Regulation and Payment Between China and the United States

Documenti analoghi

• Mapping the Clinical Development Trajectory of Cell and Gene Therapy Products
  di: Magdi Elsallab, et al.
  Pubblicazione: (2024)
• Assessment of Efficacy Evidence for Approvals of Novel Drugs in China Between 2018 and 2022
  di: Yang Xu, et al.
  Pubblicazione: (2024)
• Comparative Analysis of Post‐Authorization Measures for Advanced Medicinal Products Authorized in the European Union and in the United States of America Between 2009 and 2023
  di: Diana Mandslay, et al.
  Pubblicazione: (2024)
• Clinical Pharmacology Considerations for the “Off‐the‐Shelf” Allogeneic Cell Therapies
  di: Hardik Mody, et al.
  Pubblicazione: (2024)
• Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges
  di: D. Max Smith, et al.
  Pubblicazione: (2025)